Eversept Partners LP Purchases Shares of 105,106 OptiNose Inc (NASDAQ:OPTN)

Eversept Partners LP purchased a new stake in shares of OptiNose Inc (NASDAQ:OPTN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 105,106 shares of the company’s stock, valued at approximately $744,000.

A number of other hedge funds have also recently added to or reduced their stakes in OPTN. Wasatch Advisors Inc. bought a new stake in OptiNose during the second quarter valued at about $4,746,000. BlackRock Inc. lifted its stake in shares of OptiNose by 15.9% in the second quarter. BlackRock Inc. now owns 1,918,914 shares of the company’s stock valued at $13,586,000 after buying an additional 263,667 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of OptiNose by 8.1% in the first quarter. JPMorgan Chase & Co. now owns 2,503,969 shares of the company’s stock valued at $25,791,000 after buying an additional 187,174 shares during the period. Kornitzer Capital Management Inc. KS lifted its stake in shares of OptiNose by 12.2% in the second quarter. Kornitzer Capital Management Inc. KS now owns 554,035 shares of the company’s stock valued at $3,923,000 after buying an additional 60,175 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of OptiNose by 19.7% in the second quarter. Charles Schwab Investment Management Inc. now owns 100,040 shares of the company’s stock valued at $709,000 after buying an additional 16,457 shares during the period. Institutional investors own 64.98% of the company’s stock.

Several research firms recently weighed in on OPTN. ValuEngine upgraded shares of OptiNose from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research cut shares of OptiNose from a “buy” rating to a “hold” rating in a research note on Thursday, July 11th. BMO Capital Markets reduced their target price on shares of OptiNose from $26.00 to $24.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Finally, Royal Bank of Canada set a $20.00 target price on shares of OptiNose and gave the company a “buy” rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. OptiNose has an average rating of “Buy” and a consensus price target of $21.50.



Shares of NASDAQ OPTN traded up $0.30 during mid-day trading on Friday, hitting $7.02. The company had a trading volume of 1,016 shares, compared to its average volume of 260,411. The company has a debt-to-equity ratio of 1.06, a current ratio of 6.60 and a quick ratio of 6.43. The business’s 50-day simple moving average is $6.20 and its 200-day simple moving average is $7.92. OptiNose Inc has a 12 month low of $4.44 and a 12 month high of $14.23. The firm has a market cap of $278.48 million, a P/E ratio of -2.61 and a beta of 0.60.

OptiNose (NASDAQ:OPTN) last released its earnings results on Monday, August 12th. The company reported ($0.66) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.09. OptiNose had a negative net margin of 670.20% and a negative return on equity of 102.10%. The business had revenue of $6.68 million during the quarter, compared to analysts’ expectations of $7.74 million. As a group, sell-side analysts predict that OptiNose Inc will post -2.74 EPS for the current year.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

See Also: Do equity income investments outperform growth and income investments?

Want to see what other hedge funds are holding OPTN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptiNose Inc (NASDAQ:OPTN).

Institutional Ownership by Quarter for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.